Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
236
-
Total 13F shares, excl. options
-
91.6M
-
Shares change
-
-1.14M
-
Total reported value, excl. options
-
$2.73B
-
Value change
-
-$6.54M
-
Put/Call ratio
-
0.31
-
Number of buys
-
107
-
Number of sells
-
-113
-
Price
-
$29.80
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q4 2024
297 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q4 2024.
NovoCure Ltd - Common Stock (NVCR) has 236 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.6M shares
of 112M outstanding shares and own 81.77% of the company stock.
Largest 10 shareholders include FMR LLC (16.2M shares), BlackRock, Inc. (13M shares), VANGUARD GROUP INC (11.8M shares), Capital International Investors (8.87M shares), Capital World Investors (4.82M shares), Soleus Capital Management, L.P. (2.74M shares), STATE STREET CORP (2.64M shares), GEODE CAPITAL MANAGEMENT, LLC (2.4M shares), T. Rowe Price Investment Management, Inc. (1.69M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.68M shares).
This table shows the top 236 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.